Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Vektor has not published a global access plan for its vaccine.
Vektor has not published a human rights statement on its website.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
Vektor has not committed to a responsible licensing mechanism such as C-TAP or the MPP.
EpiVacCorona was patented on Dec 07th, 2020. The Vektor State Research Center is a government-run industry, and President Vladimir Putin has declared support to the patent waiver. However, there has been no explicit statement from the Vektor Center on not enforcing patents.
Vektor has not signed an agreement with the ACT Accelerator.
The vaccine has been licensed to Venezuela. It is unclear whether this deal is non-exclusive and what type of manufacturing it involves.
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]